LegoChem Biosciences and Iksuda enter Licensing Agreement for Antibody Drug Conjugate program
Iksuda gains worldwide rights to LCBs anti-CD19 ADC LCB73 for development and commercialization in B-cell cancers.
Preclinical data of LCB73 along with clinical outcomes of other CD19-targeted therapies suggest that this ADC represents an effective option for the treatment of various B-cell haematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma – thus matching Iksuda’s goal to develop best-in-class ADCs for hard-to-treat cancers with high unmet need.
Iksuda plans to advance LCB73 into the clinic in a the most efficient manner, utilizing its extensive UK and US based ADC expertise to drive pre-clinical and clinical development activities.
